|1.||Montorsi, Francesco: 12 articles (11/2015 - 11/2004)|
|2.||Burnett, Arthur L: 12 articles (05/2014 - 05/2006)|
|3.||Kloner, Robert A: 12 articles (05/2014 - 03/2004)|
|4.||Maggi, Mario: 12 articles (09/2013 - 03/2007)|
|5.||Jackson, Graham: 11 articles (05/2014 - 12/2002)|
|6.||Porst, Hartmut: 11 articles (01/2013 - 08/2006)|
|7.||Aversa, Antonio: 10 articles (04/2015 - 01/2006)|
|8.||Rosen, Raymond C: 10 articles (03/2015 - 11/2003)|
|9.||Sandner, Peter: 9 articles (01/2015 - 12/2006)|
|10.||Carson, Culley C: 9 articles (09/2013 - 12/2002)|
07/01/2007 - "Mapping the 3D-QSAR models to the active site of PDE5 provides a new insight into the protein-inhibitor interactions and helpful in designing potent and selective PDE5 inhibitors for the treatment of erectile dysfunction."
10/01/2015 - "In the analysis, we found significantly improved IELT in the combination use group compared with the use of SSRIs (mean differences [MD], 1.01; 95% confidence interval [CI], 0.61-1.41; P <.01) or PDE-5 inhibitors alone (MD, 1.11; 95% CI, 0.79-1.43; P <.01) for PE whether or not these patients suffered from erectile dysfunction. "
11/01/2013 - "The phosphodiesterase type 5 (PDE5) inhibitors are generally well tolerated and effective for treating erectile dysfunction (ED), including in patients with significant comorbidity. "
03/01/2011 - "Although improved nerve-sparing techniques have reduced the incidence of nerve injury, and the administration of phosphodiesterase type 5 inhibitors has revolutionized the treatment of erectile dysfunction, this problem remains a considerable challenge. "
08/01/2006 - "Of the current options available to treat erectile dysfunction, oral phosphodiesterase type 5 (PDE5) inhibitors are the recommended first-line treatment. "
|2.||Prostatic Hyperplasia (Benign Prostatic Hyperplasia)
03/01/2013 - "Clinical trials of phosphodiesterase type 5 inhibitors (PDE5-Is) have consistently demonstrated a significant reduction in lower urinary tract symptoms (LUTS) and small urinary flow rate changes in men with benign prostatic hyperplasia (BPH). "
02/06/2015 - "Are phosphodiesterase type 5 inhibitors effective for the management of lower urinary symptoms suggestive of benign prostatic hyperplasia?"
12/01/2013 - "There are many studies related to the use of PDE-5 inhibitors as a monotherapy or combination therapy with alpha-blockers for lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH). "
11/01/2015 - "The aim of this systematic review is to determine the comparative effectiveness and safety of phosphodiesterase 5 inhibitors (PDE5-Is) and α-blockers used alone or combined for the treatment of lower urinary tract symptoms (LUTS) due to benign prostatic hyperplasia (BPH). "
07/01/2014 - "[Phosphodiesterase type 5 inhibitors for lower urinary tract symptoms induced by benign prostatic hyperplasia: an update]."
|3.||Hypertension (High Blood Pressure)
07/15/2014 - "Prompted by the role of PDE5 and its closely associated cAMP and cGMP in hypertension, we have attempted to discover novel PDE5 inhibitors through ligand based virtual screening. "
08/15/2013 - "PDE 5 inhibitors may have, therefore, the potential to reduce glomerular hypertension. "
01/01/2007 - "This case report shows for the first time, that phosphodiesterase 5 inhibitors lower both portal and pulmonary pressure in portopulmonary hypertension."
01/01/2007 - "Phosphodiesterase 5 inhibitors lower both portal and pulmonary pressure in portopulmonary hypertension: a case report."
01/01/2007 - "PDE-5 inhibitors lower portal and pulmonary pressure in portopulmonary hypertension."
|4.||Pulmonary Hypertension (Ayerza Syndrome)
07/01/2008 - "These data suggest that phosphodiesterase type 5 inhibitors may have effects that distinguish them from other treatments for pulmonary hypertension and merit further study."
12/26/2005 - "In addition to their benefits in the treatment of ED, preliminary studies suggest that PDE5 inhibitors enhance endothelial function in patients with CHF and have beneficial effects on pulmonary hemodynamics and exercise capacity in patients with pulmonary hypertension. "
09/01/2010 - "[PDE5 inhibitors in the treatment of pulmonary hypertension]."
02/01/2010 - "Phosphodiesterase type 5 inhibitors (PD5I) are known to reduce pulmonary hypertension (PH). "
01/01/2010 - "The available evidence suggests PDE5 inhibitors can attenuate altitude-induced pulmonary hypertension without significantly affecting systemic blood pressure or heart rate."
08/01/2014 - "Strategies targeting MDSC function with PDE5 inhibitors represent a novel approach that can augment the efficacy of tumor-directed therapies."
03/01/2015 - "Many clinical trials with PDE5 inhibitors have focused on the potential cardiovascular and anti-cancer benefits. "
11/01/2015 - "PDE5 expression in human thyroid tumors and effects of PDE5 inhibitors on growth and migration of cancer cells."
02/01/2013 - "These results suggest that PDE5 inhibitors could be used to elevate cGMP levels to induce 67LR-mediated, cancer-specific cell death."
09/16/2008 - "Collectively, this data demonstrates that oral administration of PDE5 inhibitors selectively increases BTB permeability and enhances anti-tumor efficacy for a chemotherapeutic agent. "
|5.||Type 5 Cyclic Nucleotide Phosphodiesterases
|6.||Nitric Oxide (Nitrogen Monoxide)
|7.||Idiopathic pulmonary hypertension
|8.||Endothelin Receptors (Endothelin Receptor)
|1.||Drug Therapy (Chemotherapy)
|2.||Prostatectomy (Retropubic Prostatectomy)
|4.||Self Administration (Administration, Self)
|5.||Heart Transplantation (Grafting, Heart)